Bravo Multinational Incorporated (BRVO) Posts Company Update

Toronto, Canada –May 27, 2016– Bravo Multinational Incorporated (BRVO: OTCQB) posts an update of significant corporate accomplishments and goals.

Bravo has been up-listed to the OTCQB trading platform and as of May 26, 2016, has a Morningstar rating of ‘3’ stars.

Effective May 25, 2016, Bravo’s Board of Directors terminated its contractual relationship with FMW Media Works Corp.  Also, the Directors canceled the Company’s intent to pursue the recently signed MOU with Pet Longevity. Bravo has demanded the recall all 20,500,000 million restricted and S8 shares issued as part of this contract and two other consulting agreements.

Bravo is currently negotiating a potential purchase agreement with a large gold mining property and claim owner in Northern Ontario, Canada’s gold country. Further details will be released when available on this exciting new project.

Bravo’s President will travel to Central America in June to continue negotiation and solidify pending agreements on the following:

–    The purchase of two (2) municipal casino licenses located in San Salvador, El Salvador.

–    Complete negotiations for a business consulting agreement with a national sports franchise in El Salvador.

–    Complete agreements to establish import arrangements with a country-wide grocery chain in El Salvador.

Bravo will release more details on the plans and expectations for the recently closed transaction on May 6, 2016, for the purchase of 500 slot and video poker machines in Nicaragua from Centro de Entretenimiento y Diversion Mombacho SA.   Management further anticipated expansion plans for this project, and will report on the expected growth as it becomes available.

Bravo has been in discussions with management of casino operations in San Andres, Colombia, and anticipates that Bravo could enter into a new lease agreement, placing the Company’s owned “Casino Equipment” into operations.

Bravo began the procedure to take legal actions against Silver Falcon Mining, Inc. (SFMI.OTCPINK) which is in serious default of its lease payment obligations, owing Bravo over $2.4 million.

Bravo has begun the procedure to “Stop Transfer” and “Cancel” some of the suspect share issuances.  Management acknowledges this is a time-consuming task with OVER 100 MILLION suspect share issuances, and it may take several months to complete in multiple stages.  Progress reports will become available as BRVO makes its way through the cancellation processes.

A new BRAVO website, BRAVOMULTINATIONAL.COM should be online within the first couple of weeks of June 2016.

About Bravo Multinational Incorporated:

Bravo Multinational Incorporated (OTCQB: BRVO) is a diversified Company, with casino equipment holdings in Central and South America as well as gold / silver mining properties and claims in North America. Bravo’s growth strategy, driven by partnerships, acquisitions, and new ventures should result in financially viable and profitable corporate divisions.

For further information about Bravo Multinational Incorporated, please contact, YES INTERNATIONAL, 757-306-6090 or yes@yesinternational.com.

Bravo Multinational Incorporated cautions that the statements made in this press release and other forward looking statements made on behalf of the Company may be affected by such other factors including, but not limited to, vagaries of trade, market competition and other risks detailed herein and from time to time in the U.S. Securities and Exchange Commission filings of the Company.

NUTROGANICS ANNOUNCES ADDITION OF KEITH FRANKEL TO COMPANY’S ADVISORY BOARD  

BETHESDA, Md., May 25, 2016 – Nutroganics, Inc. (OTCPINK:NUTT) (“Nutroganics”) announced today that Keith Frankel has joined the Company’s advisory board.

Mr. Frankel is a well-known executive and investor in the nutrition industry.   He founded Vitaquest which he has grown to be a $300 million contract manufacturer and distributor of nutraceuticals and nutritional supplements.  He also serves as President of Celmark International, Inc. and on the Executive Board of Mid Ocean Partners, a private investment firm that specializes in middle market investments in the United States (www.midoceanpartners.com).

David Sackler, Nutroganics’ President & CEO, said, “We are thrilled that Keith has agreed to join our advisory board. He brings enormous industry credibility and relationships to Nutroganics.   We look forward to working with him as he helps Nutroganics become a larger, more successful company.”

About Nutroganics:

Nutroganics, Inc. acquires and grows revenue-generating businesses operating in the healthy lifestyle marketplace, and seeks to capitalize on synergies from manufacturing through distribution. Nutroganics owns Silverbow Honey Company, a producer and packager of honey products founded in 1945 and based in Moses Lake, Washington and NuStar Manufacturing, LLC, a Utah based packager of nutritional products and supplements.

For more information, contact David Sackler at dsackler@nutroganics.com or (240) 223-1000, and/or Rich Kaiser, Investor Relations, YES INTERNATIONAL, rich@yesinternational.com, 757-306-6090.

Forward-Looking Statements:

 This release may contain forward-looking statements, which involve known and unknown risks, uncertainties, and other factors, which may cause Nutroganics’ actual results, performance, or achievements to be materially different from actual future results expressed or implied by the forward-looking statements. We undertake no obligation to update any forward-looking statements after the date of such statements.  Please review the Company’s most recent public filings at www.otcmarkets.com for a list of risk factors that potential investors should carefully consider.

Bravo Multinational Incorporated (BRVO) Up-listed Trading On To OTCQB

Toronto, Canada –May 24, 2016– Bravo Multinational Incorporated (BRVO: OTCQB) effective today, up-listed the Company’s stock on to the OTCQB trading platform. The Company would like to thank OTC Market Groups compliance department and management for its assistance and cooperation during this transition.

Paul Parliament, Bravo CEO, states, “The OTCQB trading platform at OTCMARKETS.COM allows the Company to obtain much greater market exposure as it initiates its next steps and advances the growth of its business divisions. The OTCQB, along with available status boosting upgrades such as ‘Blue Sky Monitoring’ and ‘Morningstar Reports,’ will lend to the quality image we expect to maintain and eventually exceed for the valued shareholders of this Company.”

The Company is diligently working toward the completion of initial agreements on four of its planned business ventures.  As Bravo advances, information as such will be forthcoming, as soon as available.

A new BRAVO website, BRAVOMULTINATIONAL.COM should be online within the first couple of weeks of June 2016.

For further information about Bravo Multinational Incorporated, contact  YES INTERNATIONAL, at yes@yesinternational.com or 757-306-6090.

About Bravo Multinational Incorporated:

Bravo Multinational Incorporated (OTCQB: BRVO) is a diversified Company, holding casino equipment holdings in Central and South America as well as gold / silver mining properties and claims in North America. Bravo’s growth strategy, driven by partnerships, acquisitions, and new ventures should result in financially viable and profitable corporate divisions.

Bravo Multinational Incorporated cautions that the statements made in this press release and other forward looking statements made on behalf of the Company may be affected by such other factors including, but not limited to, vagaries of trade, market competition and other risks detailed herein and from time to time in the U.S. Securities and Exchange Commission filings of the Company.

Predictive Biotech, Inc. Announces a Beta Launch of Spine Deformity Molecular Diagnostic Test, Initially Focused on Scoliosis

Beta launch of new assay is the first of several spine related product introductions

SALT LAKE CITY, UT–(May 19, 2016)– Predictive Technology Group, Inc. (OTC PINK: PRED), a life sciences technology holding company, through its subsidiary Predictive Biotech, Inc., announces beta launch of a new molecular diagnostic assay developed to predict the severity of spine deformities and syndromes.

Eric Olson, Predictive Biotech’s President and CEO, stated, “We are pleased to move forward with our spinal deformity molecular diagnostic test and continue the development work on companion spinal treatment product candidates. Our commercialization strategy is to focus on collaboration with spine societies to jointly develop and improve the technologies to best meet surgeon members’ clinical needs. This new assay improves upon the work that was completed by individual surgeons from the Scoliosis Research Society (SRS) who participated in an unparalleled clinical study on scoliosis.”

Mike Schramm, Predictive Biotech’s Director of Intellectual Property, said, “In addition to the beta launch of a new ‘Spine Deformity Test’, initially focused on scoliosis, we look forward to the imminent grant of the US Patent application 20150127105 covering this technology.  The allowance of the ‘105 application was decided by the  United States Patent and Trademark Office’s Patent Trial and Appeal Board  and, we believe, supercede any other spinal deformity related molecular diagnostic tests, including molecular diagnostic for scoliosis. The claims of the ‘105 application are of such breadth that any treatment of any spine deformity disease falls within the scope of this patent.

Further, Schramm states, “We also believe this allowance will play a significant role in providing protection for Predictive’s planned commercial offering of other molecular diagnost tests and companion treatments. The ‘105 application builds upon other Predictive patents including 8,123,787, 8,641,738, and 20150337373.”

PRED’s subsidiary Predictive Biotech strives to provide its surgeon customers with the highest quality predictive diagnostics and treatment solutions that can ultimately benefit their patients.

For further information about PRED, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090, rich@yesinternational.com and info@predictivetechnologygroup.com

About Predictive Technology Group, Inc.

 Predictive Technology Group, Inc. (OTC PINK: PRED), through its wholly owned subsidiaries, revolutionizes the treatment of severe and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. The Company develops and/or acquires proprietary technologies that open windows into the origin of human disease and the role that genes and their related proteins play in diseases’ onsets and progressions. PRED’s subsidiaries use gene-based information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to prevent and treat diseases.

Forward-Looking Statements

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.

 

Bravo Multinational Incorporated (BRVO) Completes a New Casino Gaming Business Venture in Nicaragua

Toronto, Canada –May 17 , 2016– Bravo Multinational Incorporated (BRVO: OTCPINK) completed an acquisition transaction on May 6, 2016 with Centro de Entretenimiento y Diversion Mombacho S.A., a well respected and established company with its head-quarters located in Managua, Nicaragua.

In this transaction, Bravo will purchase in total 500 slot and video poker gaming machines, in a part stock and part seller financed transaction.  All machines have been fully Nationalized (import tax’s paid) and are to be operated under a long-term (year 2033) countrywide national license.

Paul Parliament, Bravo CEO, stated, “We at Bravo are very excited to move forward with this aggressive project for which we see very positive future rewards.  Also, the many additional doors it will open and the foothold this will establish for BRVO in Nicaragua is extremely promising. The current economic climate in Nicaragua is very positive with data showing in 2015 an economic growth rate of 4.9% driven by high growth in the construction and manufacturing sectors.”

Mr. Julios Kosta, Centro de Entretenimiento Diversion Mombacho S.A., Presidente , stated, “My company has strong established business connections with over 14-years gaming experience in the Nicaraguan market place and throughout Central and South America which will provide numerous long-term benefits and support for this new relationship with Bravo. We look forward to working closely with Mr. Parliament and his team to develop not only this transaction but to also expand into many other mutually beneficial business opportunities.”

Full transactional details on this completed business venture are contained within a US SEC FORM 8-K filing.

The Company executives remain confident that this transaction is a solid financial move, providing a long-term steady revenue source for Bravo Multinational Incorporated.

BRVO continues to advance several of its other business operations, and information as such will be forthcoming when available.

About Bravo Multinational Incorporated:

Bravo Multinational Incorporated (OTCPINK: BRVO) is a diversified Company, with casino equipment holdings in Central and South America as well as gold / silver mining properties and claims in North America. Bravo’s growth strategy, driven by partnerships, acquisitions, and new ventures should result in financially viable and profitable corporate divisions.

For further information about Bravo Multinational Incorporated please contact, YES INTERNATIONAL, 757-306-6090 or yes@yesinternational.com.

Bravo Multinational Incorporated cautions that the statements made in this press release and other forward looking statements made on behalf of the Company may be affected by such other factors including, but not limited to, vagaries of trade, market competition and other risks detailed herein and from time to time in the U.S. Securities and Exchange Commission filings of the Company.

Predictive Biotech, Inc. Completes Development Of Allograft Stem Cell Liquid Suspension Product

Company Introduces Its Latest Innovation In Regenerative Treatment Solutions

Salt Lake City, UT — (May 16, 2016) – Predictive Technology Group, Inc. (OTC PINK: PRED), announces that its wholly-owned subsidiary, Predictive Biotech, Inc. has finalized the development process of a new allograft stem cell product derived from umbilical cord blood (UCB).

The use of UCB stem cells has gained popularity in medical science owing to their ability to transform into any type of human cells. UCB refers to the blood and tissue that remains in the attached umbilical cord and placenta after childbirth. UCB derived stem cells are considered unique in their applicability in treating many different diseases and disorders including fusion, wound healing, pain management, genetic and hematopoietic disorders.

Eric Olson, President and CEO of Predictive Biotech, Inc., said, “We are very excited to announce that we have completed the development of our latest biologic product. The ‘CoreCell’ liquid suspension product which is rich in proteins and cells is a strong addition to our current regenerative product portfolio.”

Mr. Olson continues, “The new ‘CoreCell’ product added to our allograft portfolio brings together a full selection of regenerative solutions in three core products, UBC, amniotic liquid suspension products, and amniotic membrane. This group of allograft products gives our clinicians the flexibility to choose the optimum solution depending on the patient indication and personal preference.

Predictive Biotech is currently negotiating with several large orthobiologic distributors to launch the product domestically and internationally. The Company is also considering private label opportunities and plans to eventually distribute the product through its own direct sales organization.

About Predictive Technology Group, Inc.

Predictive Technology Group, Inc. (PRED), through its wholly owned subsidiaries, revolutionizes the treatment of severe and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. The Company develops and acquires proprietary technologies that open windows into the origin of human illness and the role that genes and their related proteins play in diseases’ onsets and progressions. PRED’s subsidiaries use gene-based information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to prevent and treat diseases effectively, www.predictivetechnologygroup.com and www.predrx.com.

About Predictive Biotech, Inc.

Predictive Biotech, Inc. is a cellular and regenerative medicine company, focused on the development, processing and distribution of innovative allograft tissues, stem cells and biomaterials for the treatment of serious and debilitating diseases. The company develops and acquires technologies that incorporate the use of genome sequencing with proprietary tissue/stem cell recovery to ensure the highest quality treatment options for its surgeon customers and their patients.

For further information, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090 and yes@yesinternational.com and info@predicitivetechnologygroup.com.

Forward-Looking Statements

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.

Bravo Multinational Incorporated (BRVO) Files OTCQB Application to OTC Market Group, Inc.

Toronto, Canada –May 5, 2016– Bravo Multinational Incorporated (BRVO: OTCPINK) completes a crucial step in the preparation of the Company by submitting an application to enable BRVO to up-list to the OTCQB trading platform. The Company’s application is now under review by OTC Market Groups compliance department.

Paul Parliament, Bravo CEO, states, “The OTCQB trading platform at OTCMARKETS.COM is an ideally suited trading level from which to launch our future business operations and we feel will attract the quality of investor looking for long-term growth and stability that we intend to deliver. The executives are very confident the OTCQB platform will assist in bringing this Company’s profile to new heights and provide the respectability deserving of the efforts put forward to date.”

Soon, BRVO’s first newly completed and planned business operation to be announced in an 8-K filing and subsequent press release(s).  As BRVO continues to advance its business operations, information as such will be forthcoming when available.

Management remains confident that its up-list application approval for the OTCQB to be completed before the upcoming FWM Media Works’ “Bravo Multinational” program “New To The Street” T.V. taping and presentation at the Capital Grill in NYC, NY on May 25, 2016.

For further information about Bravo Multinational Incorporated contact, Kara Craig, YES INTERNATIONAL, 757-306-6090, and yes@yesinternational.com.

About Bravo Multinational Incorporated:

Bravo Multinational Incorporated (OTCPINK: BRVO) is a diversified Company, holding casino equipment in South America and gold / silver mining properties in North America. BRVO’s growth strategy, driving by acquisitions and new ventures should result in financially viable and profitable corporate divisions.

Bravo Multinational Incorporated cautions that the statements made in this press release and other forward looking statements made on behalf of the Company may be affected by such other factors including, but not limited to, vagaries of trade, market competition and other risks detailed herein and from time to time in the U.S. Securities and Exchange Commission filings of the Company.